At a glance
ClinicalIndex Comparison RecordN/ACompleted· 27 enrolled
Drug / intervention
Oral Omega-3-acid ethyl esters +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome
In Brief
A clinical study evaluating Oral Omega-3-acid ethyl esters and Placebo corn oil capsule for Dry Eye Syndrome. Completed, enrolled 27 participants across 1 site.
Detailed Summary
The investigators hypothesize that oral omega-3-acid ethyl esters (Lovaza, GlaxoSmithKline, Research Triangle Park, NC) will decrease dry-eye related symptoms as well as clinical markers associated with dry eye disease (Schirmer-1 test values, positive vital staining with lissamine green, and fluorescein tear break-up time) when compared to administration of placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye Syndrome
CountriesUnited States
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 2010
Enrollment StartJul 2010
Primary CompletionAug 2014
Study CompletionJun 2015
TodayJul 2026
First PostedApr 21, 2010
Enrollment StartJul 1, 2010
Primary CompletionAug 1, 2014
Study CompletionJun 15, 2015
TodayJul 2, 2026
Enrollment to primary: 4.1 yearsPosted 16.2 years ago
Interventions
Oral Omega-3-acid ethyl estersdrug
1 gram capsule by mouth four times daily for 45 days
Placebo corn oil capsuledrug
1 gram by mouth 4 times daily for 45 days